10x Genomics News

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)

TipRanks10:11

10x Genomics to Present at the BofA Securities 2024 Healthcare Conference

Yahoo Finance04:05

10x Genomics First Quarter 2024 Earnings: In Line With Expectations

Yahoo FinanceMay 2 18:34

Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies

TipRanksMay 2 14:03

UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating

10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09

MT NewswiresMay 2 00:59

10x Genomics Cut to Hold From Buy by TD Cowen

10x Genomics Cut to Hold From Buy by TD Cowen

Dow JonesMay 2 00:37

TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.

TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.

Zhitong FinanceMay 2 00:30

10x Genomics, Inc. (NASDAQ:TXG) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 1 23:33

10x Genomics Is Maintained at Buy by Stifel

10x Genomics Is Maintained at Buy by Stifel

Dow JonesMay 1 21:12

10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel

10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel

Dow JonesMay 1 21:12

Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53

Stifel analyst Daniel Arias maintains 10x Genomics with a Buy and lowers the price target from $63 to $53.

Analyst UpgradesMay 1 21:01

10x Genomics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 105.43% Stifel $63 → $53 Maintains Buy 04/29/2024 93.8% Canaccord Genuity $65 → $50 Maintains B

BenzingaMay 1 21:00

Earnings Call Summary | 10x Genomics(TXG.US) Q1 2024 Earnings Conference

The following is a summary of the 10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript:Financial Performance:10x Genomics reported Q1 total revenue growth of 5% to $141 million.Consumption revenu

Futu NewsMay 1 19:26 · Conference Call

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)

TipRanksMay 1 18:50

Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)

TipRanksMay 1 15:41

The European Unified Patent Court Clears Curio Seeker With Respect To Claim 1 Of EP 2697391 Asserted By 10x Genomics

The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ:TXG). The UPC has also ordered Curio B

BenzingaMay 1 15:27

10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...

Yahoo FinanceMay 1 15:27

Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)

Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a

BusinesswireMay 1 13:01

10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.

10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.

BenzingaMay 1 05:58

10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches

Yahoo FinanceMay 1 05:43